Neurotech International Ltd. · ASX:NTI
Neurotech International — NWR Virtual Healthcare Conference 2025
22 slides from Neurotech International's conference presentation, Mar 20, 2025
Slide 1: Neurotech Presentation at NWR Virtual Healthcare Conference
ASX Announcement 20 March 2025 Neurotech Presentation at NWR Virtual Healthcare Conference Neurotech International Limited (ASX: NTI) (“Neurotech” or “the Company”), a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders, will today present
Slide 2: About Neurotech
About Neurotech About Neurotech International Limited (ASX:NTI)) is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. Neurotech has completed a Phase II/III randomised,
Slide 3: Advancing Neuroscience Transforming Lives
For personal use only Advancing Neuroscience Transforming Lives Dr Anthony Filippis Chief Executive Officer & Managing Director Corporate Overview March 2025 0
Slide 4: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements do not relate strictly to historical or current facts and may be accompanied by words such as ‘c
Slide 5: Neurotech International is a clinical stage biotech company
Neurotech International (ASX: NTI) is a clinical stage biotech company • NTI164, is an orally available cannabinoid therapy for the treatment of neurological disorders For personal use only • Autism Spectrum Disorder (ASD) • Positive clinical data from single arm NTIASD01 phase I/II study • Positive
Slide 6: Neurotech's pipeline comprises clinical programs in neurological and rare neurological disorders
Neurotech’s pipeline comprises clinical programs in neurological and rare neurological disorders of children where neuroinflammation is involved For personal use only NTI164 Targets neuroinflammation PRECLIN. PHASE 1 PHASE 2 PHASE 3 MARKET Neurological disorders PI: Phase I/II data Autism Spectrum D
Slide 7: Targeting large markets where there is a clear unmet need
Targeting large markets where there is a clear unmet need Incidence rate Gender prevalence Genetic cause Onset of symptoms Global cases For personal use only Autism Spectrum 100’s of genes Appear before Estimated Disorder ~1 in 36 4x more common in implicated. Influenced age 3 children aged 8 in US
Slide 8: What is NTI164?
What is NTI164? • Cannabinoid derived therapy For personal use only • Proprietary formulation with a novel combination of cannabinoids • Patents cover composition, use and formulations • Targeted therapy • Designed to target neuroinflammation by suppressing a wide range of inflammatory cytokines, im
Slide 9: NTI164 has shown compelling evidence of clinical efficacy
NTI164 has shown compelling evidence of clinical efficacy ASD HARMONY Phase 2/3 CGI-I Total Score Rett Syndrome Phase 1/2 CGI-I Total Score^ PANS Phase 1/2 CGI-I Total Score For personal use only Clinical trial results ASD Rett PANS CGI-I (overall improvement) 84%* 93%* 87%* CGI-S (severity of illne
Slide 10: Pivot company towards revenue and commercialisation to grow shareholder value
Pivot company towards revenue and commercialisation to grow shareholder value For personal use only IND Pursue development & ODD approval partnering strategy for ASD/Rett in US Rett Rett/ASD 4Q24 1H25 4Q25 1H26 4Q26 1H27 4Q27 ODD IND Rett Progress EU Rett Potential 1st revenues Rett submission Prov
Slide 11: US 'go to market' strategy
US ‘go to market’ strategy For personal use only Partnering Confirm data IND FDA meeting IND approval strategy acceptability submission opens Ensure ICH-GCP Australian FDA review and FDA grants Licensing deals compliance (21 clinical data feedback on approval to CFR 312.120) data sufficiency proceed
Slide 12: The competitive landscape is not crowded with few approved therapies
The competitive landscape is not crowded with few approved therapies Early Development Late Development Approved Risperdal firstly developed by For personal use only Autism Spectrum Disorder NTI164 Janssen-Cilag & Ablify by Otsuka Several off-label use of other neuropsychiatric drugs which Originall
Slide 13: The commercial opportunity for NTI164 is substantial
PRELIMINARY The commercial opportunity for NTI164 is substantial, with a potential market size of >US$10 billion, reflecting favorable pricing dynamics Comparator Revenues (2022-24) Comparator Pricing NTI164 Commercial Opportunity For personal use only Company Product 2024 2023 2022 Company Product
Slide 14: Market comparators provide a strong precedent for NTI164
Market comparators provide a strong precedent for NTI164 Market comparators Company Comparable pipeline Market Cap For personal use only (cannabidiol, approved) ~ US$8.5B (approved) ~ US$2.9B NNZ-2591 Phase 2 data including Angelman, Phelan McDermid, Pitt Hopkins ~AU$1.6B Anavex 2-73 (Blarcamesine)
Slide 15: Broad outreach program to nurture potential future partners for NTI164
The company will commence a broad outreach program to socialise and nurture potential future partners for NTI164 Benchmarks for Phase II/III Neuro Disease Partnering For personal use only Typical Structure of Pharma Partnering Transactions Transactions (2016 – 2025 YTD) (n=64) Low Median High Upfron
Slide 16: Partnering opportunity for NTI164 is substantial
Partnering opportunity for NTI164 is substantial, with benchmark transactions suggesting significant value potential Licensing Transactions Deal Value Licensee Licensor Key Asset(s) Key Indication(s) Stage Date For personal use only (US$) PTC518 Huntington’s disease Phase II Nov 2024 $2.9B ABV-1504/
Slide 17: Neurotech Board brings extensive international experience
Neurotech Board brings extensive international experience in drug development, finance and commercialisation For personal use only Mr Mark Davies Dr Anthony Filippis Mr Max Johnston Board Chair Managing Director & CEO Non-Executive Director 20 years experience in 25 years of life sciences Over 40 ye
Slide 18: Neurotech's clinical advisory/KOL committee
Neurotech’s clinical advisory/KOL committee provides extensive expertise in clinical development For personal use only Professor Carolyn Ellaway Professor Michael Fahey Professor Russell Dale Head, Metabolic Genetics Head, Paediatric Neurology Head, Paediatric Neurology Children’s Hospital, Monash C
Slide 19: Neurotech financial position and value drivers
AS AT 19 MAR 2025 Neurotech financial position and value drivers Corporate Fundamentals For personal use only Market Capitalisation: ~AU$ 39M Primary Listing: ASX: NTI Shares on Issue: 1.04 Billion Financial Position Cash Balance (31 Dec 24): AU$ 5.9 Million R&D Tax Incentive (31 Jan 25) AU$2.44M Hu
Slide 20: Value-driving catalysts on the horizon for Neurotech
Value-driving catalysts on the horizon for Neurotech CY2025 For personal use only R&D Tax Incentive - $2.44m 1Q CY2025 Manufacturing update – New partnership with ECC 1Q CY2025 Neurotech Receives Positive Opinion for Orphan Designation in Rett Syndrome for NTI164 in Europe 1Q CY2025 Completion of Ph
Slide 21: What are families and clinicians saying about NTI164?
What are families and clinicians saying about NTI164? “In my view, results obtained with “From 20 “He’s going NTI164 are truly remarkable and “I feel as meltdowns to school unprecedented. My team and I For personal use only though my a day to camp for are excited to be part of this life- son just ma
Slide 22: Contact Details
For personal use only Contact Details Neurotech Investor Relations info@neurotechinternational.com This presentation has been authorised by the Board of Neurotech International Limited www.neurotechinternational.com Neurotech International Limited (ASX: NTI) 19
Neurotech International — NWR Virtual Healthcare Conference 2025 on 6ix